| Dr. Marco Catani | Argomenti | ||||||||
|
||||||||
In questa pagina:
|
Bibliografia di riferimento: 1. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2008. CA Cancer J Clin. 2008;58(2):71-96. 2. Blot WJ, Devesa SS, Kneller RW, et al. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991;265:1287-1289. 3. Powell J, McConkey CC. Increasing incidence of adenocarcinoma of the gastric cardia and adjacent sites. Br J Cancer 1991;62:440-443. 4. Reed PI. Changing pattern of esophageal cancer. Lancet 1991;338:178. 5. Kamangar F, Dores GM, Anderson WF. Patterns of Cancer Incidence, Mortality, and Prevalence across Five Continents: Defining Priorities to Reduce Cancer Disparities in Different Geographic Regions of the World. J Clin Oncol. 2006;24(14):2137-2150. 6. Powell J, McConkey CC, Gillison EW, et al. Continuing rising trend in oesophageal adenocarcinoma. Int J Cancer 2002;102:422-427. 7. Crew KD, Neugut AI. Epidemiology of upper gastrointestinal malignancies. Semin Oncol 2004;31:450-464. 8. Kubo A, Corley DA. Marked regional variation in adenocarcinomas of the esophagus and the gastric cardia in the United States. Cancer 2002;95:2096-2102. 9. Nomura A. Stomach cancer. In: Cancer Epidemiology and Prevention, 2nd edition. Shottenfeld D, Fraumeni JF, eds. New York: NY. Oxford University Press. 1996:707-724. 10. Corley DA, Buffler PA. Oesophageal and gastric cardia adenocarcinomas: analysis of regional variation using the Cancer Incidence in Five Continents database. Int J Epidemiol 2001;30:1415-1425. 11. Parkin DM, Muir CS. Cancer Incidence in Five Continents. Comparability and quality of data. IARC Sci Publ 1992:45-173. 12. Fitzgerald RC, Caldas C. Clinical implications of E-cadherin associated hereditary diffuse gastric cancer. Gut 2004;53:775-778. 13. Huntsman DG, Carneiro F, Lewis FR, et al. Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. N Engl J Med 2001;344:1904-1909. 14. Japanese Research Society for Gastric Cancer. The General Rules for the Gastric Cancer Study in Surgery and Pathology, 12th ed. Tokyo: Kanahara Shuppan, 1993. 15. Roder JD, Bottcher K, Busch R, et al. Classification of regional lymph node metastasis from gastric carcinoma. German Gastric Cancer Study Group. Cancer 1998;82:621-631. 16. Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual, 6th ed. New York: Springer-Verlag, 2002. 17. Chau I, Norman AR, Cunningham D, et al. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol 2004;22:2395-2403. 18. Weber WA, Ott K. Imaging of esophageal and gastric cancer. Semin Oncol 2004;31:530-541. 19. Abdalla EK, Pisters PW. Staging and preoperative evaluation of upper gastrointestinal malignancies. Semin Oncol. 2004;31(4):513-529. 20. Kwee RM, Kwee TC. Imaging in local staging of gastric cancer: a systematic review. J Clin Oncol. 2007;25(15):2107-2116. 21. Kim HJ, Kim AY, Oh ST, et al. Gastric Cancer Staging at Multi-Detector Row CT Gastrography: Comparison of Transverse and Volumetric CT Scanning. Radiology. 2005;236(3):879-885. 22. Habermann CR, Weiss F, Riecken R, et al. Preoperative Staging of Gastric Adenocarcinoma: Comparison of Helical CT and Endoscopic US. Radiology. 2004;230(2):465-471. 23. Lim JS, Yun MJ, Kim M-J, et al. CT and PET in Stomach Cancer: Preoperative Staging and Monitoring of Response to Therapy. Radiographics. 2006;26(1):143-156. 24. Chen J, Cheong JH, Yun MJ, et al. Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography. Cancer 2005;103:2383-2390. 25. Rosenbaum S, Stergar H, Antoch G, Veit P, Bockisch A, Kahl H. Staging and follow-up of gastrointestinal tumors with PET/CT. Abdominal Imaging. 2006;31(1):25-35. 26. Matsumoto Y, Yanai H, Tokiyama H, et al. Endoscopic ultrasonography for diagnosis of submucosal invasion in early gastric cancer. J Gastroenterol 2000;35:326-331. 27. Tsendsuren T, Jun SM, Mian XH. Usefulness of endoscopic ultrasonography in preoperative TNM staging of gastric cancer. World J Gastroenterol. 2006;12(1):43-47. 28. Sarela AI, Lefkowitz R, Brennan MF, Karpeh MS. Selection of patients with gastric adenocarcinoma for laparoscopic staging. Am J Surg. Jan 2006;191(1):134-138. 29. Abdalla EK, Pisters PW. Staging and preoperative evaluation of upper gastrointestinal malignancies. Semin Oncol. 2004;31(4):513-529. 30. Burke EC, Karpeh MS, Jr, Conlon KC, Brennan MF. Peritoneal lavage cytology in gastric cancer: an independent predictor of outcome. Ann Surg Oncol. 1998;5(5):411-415. 31. Bentrem D, Wilton A, Mazumdar M, Brennan M, Coit D. The value of peritoneal cytology as a preoperative predictor in patients with gastric carcinoma undergoing a curative resection. Ann Surg Oncol. 2005;12(5):347-353. 32. Leichman L, Silberman H, Leichman CG, et al. Preoperative systemic chemotherapy followed by adjuvant postoperative intraperitoneal therapy for gastric cancer: A University of Southern California pilot program. J Clin Oncol 1992;10:1933-1942. 33. Ajani JA, Mayer R, Ota DM, et al. Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma. J Natl Cancer Inst 1993;85:1839-1844. 34. Hermanek P, Wittekind C. Residual tumor (R) classification and prognosis. Semin Surg Oncol 1994;10:12-20. 35. Ito H, Clancy TE, Osteen RT, et al. Adenocarcinoma of the gastric cardia: what is the optimal surgical approach? J Am Coll Surg. 2004;199(6):880-886. 36. Yu W, Choi GS, Chung HY. Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. Br J Surg. 2006;93(5):559-563. 37. Bozzetti F, Marubini E, Bonfanti G, et al. Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Italian Gastrointestinal Tumor Study Group. Ann Surg 1999;230:170-178. 38. Kajitani T, Japanese Research Society for the Study of Gastric Cancer. The general rules for gastric cancer study in surgery and pathology. Jpn J Surg 1981;11:127-145. 39. Schwarz RE, Smith DD. Clinical impact of lymphadenectomy extent in resectable gastric cancer of advanced stage. Ann Surg Oncol. 2007;14(2):317-328. 40. Sano T, Sasako M, Yamamoto S, et al. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy-Japan Clinical Oncology Group study 9501. J Clin Oncol 2004;22:2767-2773. 41. Bonenkamp JJ, Hermans J, Sasako M, et al. Extended lymph-node dissection for gastric cancer. Dutch Gastric Cancer Group. N Engl J Med 1999;340:908-914. 42 . Hartgrink HH, van de Velde CJ, Putter H, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol 2004;22:2069-2077. 43. Cuschieri A, Weeden S, Fielding J, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 1999;79:1522-1530. 44. McCulloch P, Nita ME, Kazi H, et al. Extended versus limited lymph nodes dissection technique for adenocarcinoma of the stomach. Cochrane Database Syst Rev 2004;(4):CD001964. 45. Mansfield PF. Lymphadenectomy for gastric cancer. J Clin Oncol 2004;22:2759-2761. 46. Jansen EP, Boot H, Verheij M, et al. Optimal locoregional treatment in gastric cancer. J Clin Oncol 2005;23:4509-4517. 47. van de Velde CJ, Peeters KC. The gastric cancer treatment controversy. J Clin Oncol 2003;21:2234-2236. 48. Douglass HO, Jr., Hundahl SA, Macdonald JS, Khatri VP. Gastric cancer: D2 dissection or low Maruyama Index-based surgery--a debate. Surg Oncol Clin N Am. 2007;16(1):133-155. 49. Khatri VP, Douglass HO, Jr. D2.5 dissection for gastric carcinoma. Arch Surg. 2004;139(6):662-669. 50. Degiuli M, Sasako M, Ponti A, et al. Survival results of a multicentre phase II study to evaluate D2 gastrectomy for gastric cancer. Br J Cancer 2004;90:1727-1732. 51. Jatzko GR, Lisborg PH, Denk H, Klimpfinger M, Stettner HM. A 10-year experience with Japanese-type radical lymph node dissection for gastric cancer outside of Japan. Cancer. 1995;76(8):1302-1312. 52. Sierra A, Regueira FM, Hernandez-Lizoain JL, Pardo F, Martinez-Gonzalez MA, A.-Cienfuegos J. Role of the Extended Lymphadenectomy in Gastric Cancer Surgery: Experience in a Single Institution. Ann Surg Oncol. 2003;10(3):219-226. 53. Enzinger PC, Benedetti JK, Meyerhardt JA, et al. Impact of hospital volume on recurrence and survival after surgery for gastric cancer. Ann Surg. 2007;245(3):426-434. 54. Kooby DA, Suriawinata A, Klimstra DS, et al. Biologic predictors of survival in node-negative gastric cancer. Ann Surg 2003;237:828-835. 55. Hyung WJ, Cheong JH, Kim J, et al. Application of minimally invasive treatment for early gastric cancer. J Surg Oncol 2004;85:181-185. 56. Soetikno R, Kaltenbach T, Yeh R, Gotoda T. Endoscopic Mucosal Resection for Early Cancers of the Upper Gastrointestinal Tract. J Clin Oncol. 2005;23(20):4490-4498. 57. Hull MJ, Mino-Kenudson M, Nishioka NS, et al. Endoscopic mucosal resection: an improved diagnostic procedure for early gastroesophageal epithelial neoplasms. Am J Surg Pathol. 2006;30(1):114-118. 58. Bonenkamp JJ, van de Velde CJ, Kampschoer GH, et al. Comparison of factors influencing the prognosis of Japanese, German, and Dutch gastric cancer patients. World J Surg 1993;17:410-414. 59. Ono H, Kondo H, Gotoda T, et al. Endoscopic mucosal resection for treatment of early gastric cancer. Gut 2001;48:225-229. 60. Reyes CD, Weber KJ, Gagner M, Divino CM. Laparoscopic vs open gastrectomy. A retrospective review. Surg Endosc. 2001;15(9):928-931. 61. Huscher CG, Mingoli A, Sgarzini G, et al. Laparoscopic versus open subtotal gastrectomy for distal gastric cancer: five-year results of a randomized prospective trial. Ann Surg. 2005;241(2):232-237. 62. Smalley SR, Gunderson L, Tepper JE, et al. Gastric surgical adjuvant radiotherapy consensus report - rationale and treatment implementation. Int J Radiat Oncol Biol Phys 2002;52:283-293. 63. Zhang ZX, Gu XZ, Yin WB, et al. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of the gastric cardia (AGC) - report on 370 patients. Int J Radiat Oncol Biol Phys 1998;42:929-934. 64. Hallissey MT, et al. The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: Five-year follow up. Lancet 1994;343:1309-1312. 65 .Wieland C, Hymmen U. Megavoltage therapy for malignant gastric tumors. Strahlenther Onkol 1970;140:20-26. 66. Moertel C, Childs D, Reitemeier R, et al. Combined 5-fluorouracil and supervoltage radiation therapy for locally unresectable gastrointestinal cancer. Lancet 1969;2:865-867. 67. The Gastrointestinal Study Group: The concept of locally advanced gastric cancer: Effect of treatment on outcome. Cancer 1990;66:2324-2330. 68. Hazard L, O' Connor J, Scaife C. Role of radiation therapy in gastric adenocarcinoma. World J Gastroenterol. 2006;12(10):1511-1520 69. Milano MT, Garofalo MC, Chmura SJ, et al. Intensity-modulated radiation therapy in the treatment of gastric cancer: early clinical outcome and dosimetric comparison with conventional techniques. Br J Radiol. 2006;79(942):497-503. 70. Lowy AM, et al. A pilot study of preoperative chemoradiotherapy for resectable gastric cancer. Ann Surg Oncol. 2001;8(6):519-524. 71. Ajani JA, Mansfield PF, Crane CH, et al. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol 2005;23:1237-1244. 72. Ajani JA, Mansfield PF, Janjan N, et al. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol 2004;22:2774-2780. 73. Ajani JA, Winter K, Okawara GS, et al. Phase II Trial of Preoperative Chemoradiation in Patients with Localized Gastric Adenocarcinoma (RTOG 9904): Quality of Combined Modality Therapy and Pathologic Response. J Clin Oncol. 2006;24(24):3953-3958. 74. Baeza MR, Giannini O, Rivera R, et al. Adjuvant radiochemotherapy in the treatment of completely resected, locally advanced gastric cancer. Int J Radiat Oncol Biol Phys 2001;50:645-650. 75. Moertel CG, Childs DS, O'Fallon JR, et al. Combined 5-Fluorouracil and radiation therapy as a surgical adjuvant for poor prognosis gastric carcinoma. Clin Oncol 1984;2:1249-1254. 76. Dent DM, Werner ID, Novis B, et al. Prospective randomized trial of combined oncological therapy for gastric carcinoma. Cancer 1979;44:385-392. 77. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725-730. 78. Macdonald JS, Smalley SR, Benedetti J, et al. Postoperative combined radiation and chemotherapy improves disease-free survival (DFS) and overall survival (OS) in resected adenocarcinoma of the stomach and gastrointestinal junction: Update of the results of Intergroup Study INT-0116 (SWOG 9008). 2004 Gastrointestinal Cancers Symposium: Abstract 6. 79. Cunningham D, Allum WH, Stenning SP, et al. Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer. N Engl J Med. 2006;355(1):11-20. 80. Maehara Y. S-1 in gastric cancer: a comprehensive review.Gastric Cancer 2003;6:2-8. 81. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357(18):1810-1820. 82. Nakajima T, Nashimoto A, Kitamura M, et al. Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial. Gastric Cancer Surgical Study Group. Lancet. 1999;354(9175):273-277. 83. Shah MA, Schwartz GK. Treatment of metastatic esophagus and gastric cancer. Semin Oncol 2004;31:574-587. 84. Ajani JA. Evolving Chemotherapy for Advanced Gastric Cancer. Oncologist. 2005;10(suppl_3):49-58. 85. Einzig AI, Lipsitz S, Wiernik PH, et al. Phase II trial of Taxol in patients with adenocarcinoma of the upper gastrointestinal tract: The Eastern Cooperative Oncology Group (ECOG) results. Invest New Drugs 1995;13:223-227. 86. Dank M, Zaluski J, Barone C, et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol. 2008;19(8):1450-1457. 87. Ohtsu A, Boku N, Tamura F, et al. An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer. Am J Clin Oncol 1998;21:416-419. 88. Ajani JA, Fairweather J, Dumas P, et al. Phase II study of Taxol in patients with gastric carcinoma. Cancer J Sci Am 1998;4:269-274. 89 . Kim YH, Shin SW, Kim BS, et al. Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma. Cancer 1999;85(2):295-301. 90. Sulkes A, Smyth J, Sessa C, et al. Docetaxel in advanced gastric cancer: Results of a phase II clinical trial: EORTC Early Clinical Trials Group. Br J Cancer 1994;70:380-383. 91. Einzig AI, Newberg D, Remick SC, et al. Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: The Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncol 1996;13:87-93. 92. Roth AD, Maibach R, Martinelli G, et al. Docetaxel (Taxotere)-cisplatin (TC): An effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). Ann Oncol 2000;11:301-306. 93. Ajani JA. Chemotherapy for advanced gastric or gastroesophageal cancer: defining the contributions of docetaxel. Expert Opinion on Pharmacotherapy. 2006;7(12):1627-1631. 94. Ajani JA, Mansfield PM, Dumas P. Oral etoposide for patients with advanced gastric carcinoma. Cancer J Sci Am 1999;5:112-114. 95. Ajani JA, Baker J, Pisters PW, et al. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. Cancer 2002;94:641-646. 96. Boku, N, Ohtsu A, Shimada Y, et al. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 1999;17:319-323. 97. Shirao K, Shimada Y, Kondo H, et al. Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. J Clin Oncol 1997;15:921-927. 98. Al-Batran S-E, Atmaca A, Hegewisch-Becker S, et al. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol 2004;22:658-663. 99. Louvet C, Andre T, Tigaud JM, et al. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 2002;20:4543-4548. 100. Moehler M, Haas U, Siebler J, et al. Weekly treatment with irinotecan, folinic acid and infusional 5-fluorouracil (ILF) in patients with advanced gastric cancer. Anticancer Drugs 2003;14:645-650. 101. Sumpter K, Harper-Wynne C, Cunningham D, et al. Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. Br J Cancer. 2005;92(11):1976-1983. 102. Bouche O, Raoul JL, Bonnetain F, et al. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: A Federation Francophone de Cancerologie Digestive Group Study-FFCD 9803. J Clin Oncol 2004;22:4319-4328. 103. Takiuchi T, Ajani JA. Uracil-tegafur in gastric carcinoma: A comprehensive review. J Clin Oncol 1998;16:2877-2885. 104. DeMario MD, Ratain MJ. Oral chemotherapy: Rationale and future directions. J Clin Oncol 1998;16:2557-2567. 105. Humerickhouse RA, Schilsky RL. Thymidylate synthase inhibitors in clinical development. Cancer Ther 1998;1:100-113. 106. Pyrhonen S, Kuitunen T, Nyandoto P, et al. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:587-591. 107. Murad AM, Santiago FF, Petroianu A, et al. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993;72:37-41. 108. Glimelius B, Hoffmann K, Haglund U, et al. Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol 1994;5:189-190. 109. Macdonald JS, Philip SS, Woolley PV, et al. 5-Fluorouracil, doxorubicin and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med 1980;93:533-536. 110. Cullinan SA, Moertel CG, Fleming TR, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma: Fluorouracil versus fluorouracil and doxorubicin versus fluorouracil, doxorubicin, and mitomycin. JAMA 1985;253:2061-2067. 111. Wils JA, Klein HO, Wagener DJ, et al. FAMTX (5-FU, Adriamycin and methotrexate): A step ahead in the treatment of advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer of the Gastrointestinal Tract Cooperative Group. J Clin Oncol 1991;9:827-831. 112. Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997;15:261-267. 113. Vanhoefer U, Rougier P, Wilke H, et al. Final Results of a Randomized Phase III Trial of Sequential High-Dose Methotrexate, Fluorouracil, and Doxorubicin Versus Etoposide, Leucovorin, and Fluorouracil Versus Infusional Fluorouracil and Cisplatin in Advanced Gastric Cancer: A Trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol. 2000;18(14):2648-2657. 114. Ross P, Nicolson M, Cunningham D, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 2002;20:1996-2004. 115. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group. J Clin Oncol. 2006;24(31):4991-4997. 116. Al-Batran SE, Hartmann JT, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008;26(9):1435-1442. 117. Ajani J. Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers. Cancer. 2006;107(2):221-231. 118. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358(1):36-46. 119. Kang Y, Kang WK, Shin DB, et al. Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC): Efficacy and safety results. J Clin Oncol (Meeting Abstracts). 2006;24(18_suppl):LBA4018. 120. Takahashi I, Kakeji Y, Emi Y, et al. S-1 in the treatment of advanced and recurrent gastric cancer: current state and future prospects. Gastric Cancer 2003;6:28-33. 121. Koizumi W, Kurihara M, Nakano S, et al. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology 2000;58:191-197. 122. Ohtsu A, Baba H, Sakata Y, et al. Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group. Br J Cancer 2000;83:141-145. 123. Koizumi W, Tanabe S, Saigenji K, et al. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. British Journal of Cancer. 2003;89(12):2207-2212 124. Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S- 1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9(3):215-221. 125. Ajani JA et al. Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol. 2006;24(4):663-667. 126. Lenz HJ, et al. Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study. Cancer. 2007;109(1):33-40. 127. Shah MA, Ramanathan RK, Ilson DH, et al. Multicenter Phase II Study of Irinotecan, Cisplatin, and Bevacizumab in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. J Clin Oncol. 2006;24(33):5201-5206. 128. Sun W, Powell ME, O'Dwyer P, Ansari RH, Benson AB, III. A phase II study: Combination of sorafenib with docetaxel and cisplatin in the treatment of metastatic or advanced unresectable gastric and gastroesophageal junction (GEJ) adenocarcinoma (ECOG 5203). J Clin Oncol (Meeting Abstracts). 2008;26(15_suppl):4535. 129. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007;102(8):1808-1825. 130. Ott K, Fink U, Becker K, et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol 2003;21:4604-4610. 131. Jadvar H, Tatlidil R, Garcia AA, et al. Evaluation of recurrent gastric malignancy with [F-18]-FDG positron emission tomography. Clin Radiol 2003;58:215-221. 132. Tian J, Chen L, Wei B, et al. The value of vesicant 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) in gastric malignancies. Nucl Med Commun 2004;25:825-831. 133. Glimelius B, Ekstrom K, Hoffman K, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997;8(2):163-168 . 134. Casaretto L, Sousa PLR, Mari JJ. Chemotherapy versus support cancer treatment in advanced gastric cancer: a meta-analysis. Brazilian Journal of Medical and Biological Research. 2006;39:431-440. 135. Karnofsky DA, Burchenal JH. The Clinical Evaluation of Chemotherapeutic Agents in Cancer. In: MacLeod CM (Ed): Evaluation of Chemotherapeutic Agents. New York, Columbia University Press, 1949:199-205. 136. Oken M, Creech RH, Tormey DC, Horton, J, et al. Toxicity And Response Criteria Of The Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5:649-655. 137. Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol. 1984;2(3):187-193. 138. Kim TO, Kang DH, Kim GH, Heo J et al. Self-expandable metallic stents for palliation of patients with malignant gastric outlet obstruction caused by stomach cancer. World J Gastroenterol. 2007;13(6):916-920. 139. Holt AP, Patel M, Ahmed MM. Palliation of patients with malignant gastroduodenal obstruction with self-expanding metallic stents: the treatment of choice? Gastrointest Endosc. 2004;60(6):1010-1017. 140. Lindsay JO, Andreyev HJ, Vlavianos P, Westaby D. Self-expanding metal stents for the palliation of malignant gastroduodenal obstruction in patients unsuitable for surgical bypass. Aliment Pharmacol Ther. 2004;19(8):901-905. |
|||||||
| |
ultimo aggiornamento19 September, 2010->->->-> | |||||||